Management of dupilumab-associated conjunctivitis in atopic dermatitis.
Adrenal Cortex Hormones
/ therapeutic use
Antibodies, Monoclonal, Humanized
/ adverse effects
Calcineurin Inhibitors
/ therapeutic use
Clinical Trials, Phase III as Topic
Conjunctivitis
/ chemically induced
Dermatitis, Atopic
/ drug therapy
Dermatologic Agents
/ adverse effects
Humans
Ophthalmic Solutions
/ therapeutic use
Journal
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
ISSN: 1610-0387
Titre abrégé: J Dtsch Dermatol Ges
Pays: Germany
ID NLM: 101164708
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
03
08
2018
accepted:
19
10
2018
pubmed:
16
3
2019
medline:
25
2
2020
entrez:
16
3
2019
Statut:
ppublish
Résumé
Since September 2017, the monoclonal antibody dupilumab (Dupixent
Substances chimiques
Adrenal Cortex Hormones
0
Antibodies, Monoclonal, Humanized
0
Calcineurin Inhibitors
0
Dermatologic Agents
0
Ophthalmic Solutions
0
dupilumab
420K487FSG
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
488-491Informations de copyright
© 2019 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & Sons Ltd.